In advanced STS, early clinical reports linked “M2-like” TAMs and a lower PD-L1 expression with ICB resistance.4,23 However, baseline PD-L1 status has become controversial,3 and some other conventional markers (like TMB, mismatch repair deficiency, and neoantigens) are considered impractical for STS.24,25 Recent efforts in better selecting advanced STS patient candidates for immunotherapy have focused on the lymphoid compartment, specifically TLS. This evidence concerns the gene CD274 and telomere syndrome.